(2S,3R,4R,5S,6R)-2-[5-(2-phenylethyl)naphthalen-2-yl]-3,4,5-tris(prop-2-enoxy)-6-(prop-2-enoxymethyl)thiane | 898536-38-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: (2S,3R,4R,5S,6R)-2-[5-(2-phenylethyl)naphthalen-2-yl]-3,4,5-tris(prop-2-enoxy)-6-(prop-2-enoxymethyl)thiane
• CAS: 898536-38-4
• 化学式: C₃₆H₄₂O₄S
• 分子量: 570.793
• InChiKey: JZXHVUPCHDNNPR-GJXDWMKPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.9
• 重原子数：
  41
• 可旋转键数：
  17
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  62.2
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• 1-Thio-D-Glucitol Derivatives
  申请人：Kakinuma Hiroyuki

  公开号：US20080132563A1

  公开（公告）日：2008-06-05

  The present invention provides a 1-thio-D-glucitol compound of the following formula, which shows the action of inhibiting the activity of SGLT2, a pharmaceutically acceptable salt of the compound, or a hydrate of the compound or the salt; and a pharmaceutical comprising such a compound as an active ingredient, especially, a pharmaceutical for preventing or treating diabetes, diabetes-related disease, or diabetic complication. The invention also provides a method for producing the 1-thio-D-glucitol compound and its intermediate.

  本发明提供了以下公式的1-硫代-D-葡萄糖醇化合物，该化合物显示抑制SGLT2活性的作用，该化合物的药用可接受盐或该化合物或盐的水合物；以及包含该化合物作为活性成分的制药品，特别是用于预防或治疗糖尿病、糖尿病相关疾病或糖尿病并发症的制药品。本发明还提供了制备1-硫代-D-葡萄糖醇化合物及其中间体的方法。
• 1-THIO-D-GLUCITOL DERIVATIVES
  申请人：KAKINUMA Hiroyuki

  公开号：US20110098469A1

  公开（公告）日：2011-04-28

  The present invention provides a 1-thio-D-glucitol compound of the following formula, which shows the action of inhibiting the activity of SGLT2, a pharmaceutically acceptable salt of the compound, or a hydrate of the compound or the salt; and a pharmaceutical comprising such a compound as an active ingredient, especially, a pharmaceutical for preventing or treating diabetes, diabetes-related disease, or diabetic complication. The invention also provides a method for producing the 1-thio-D-glucitol compound and its intermediate.

  本发明提供了一种以下式子的1-硫代-D-葡萄糖醇化合物，该化合物表现出抑制SGLT2活性的作用，该化合物的药学上可接受的盐或该化合物或盐的水合物；以及包含该化合物作为活性成分的制药品，特别是预防或治疗糖尿病、与糖尿病相关的疾病或糖尿病并发症的制药品。本发明还提供了一种制备1-硫代-D-葡萄糖醇化合物及其中间体的方法。
• US7910619B2
  申请人：——

  公开号：US7910619B2

  公开（公告）日：2011-03-22
• US8017792B2
  申请人：——

  公开号：US8017792B2

  公开（公告）日：2011-09-13